Phase 1/2 clinical trial to evaluate the safety and efficacy of daily intravitreal injections of KUS121 for three days in patients with non-arteritic central retinal artery occlusion
Phase of Trial: Phase I/II
Latest Information Update: 16 Mar 2018
At a glance
- Drugs KUS 121 (Primary)
- Indications Retinal vascular occlusion
- Focus Adverse reactions
- 13 Mar 2018 Status changed from active, no longer recruiting to completed.
- 19 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Nov 2016 Status changed from not yet recruiting to recruiting.